Market: NMS |
Currency: USD
Address: 3940 Trust Way
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.
📈 Benitec Biopharma Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$25.60
-
Upside/Downside from Analyst Target:
105.13%
-
Broker Call:
11
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
<0%
-
Upcoming Earnings Date:
2026-05-14
-
EPS Estimate:
-0.28
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Benitec Biopharma Inc.
| Date | Reported EPS |
|---|
| 2026-05-14 (estimated upcoming) | - |
| 2026-02-12 | -0.26 |
| 2025-11-14 | -0.22 |
| 2025-09-22 | -0.42 |
| 2025-05-14 | -0.24 |
| 2025-02-14 | -0.33 |
| 2024-11-14 | -0.48 |
| 2024-05-13 | -1.64 |
| 2024-02-13 | -2.64 |
| 2023-11-13 | -2.76 |
| 2023-05-15 | -2.72 |
| 2023-02-13 | -3.4 |
| 2022-11-10 | -7.99 |
| 2022-09-02 | -10.54 |
| 2022-05-16 | -6.8 |
| 2021-02-09 | -12.92 |
| 2020-11-13 | -41.65 |
| 2020-10-06 | -46.58 |
| 2020-08-14 | -33.32 |
📰 Related News & Research
No related articles found for "benitec biopharma".
